Preparing your results

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Identification of a primary target of thalidomide teratogenicity.

Science (New York, N.Y.) | Mar 12, 2010

http://www.ncbi.nlm.nih.gov/pubmed/20223979

Half a century ago, thalidomide was widely prescribed to pregnant women as a sedative but was found to be teratogenic, causing multiple birth defects. Today, thalidomide is still used in the treatment of leprosy and multiple myeloma, although how it causes limb malformation and other developmental defects is unknown. Here, we identified cereblon (CRBN) as a thalidomide-binding protein. CRBN forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and Cul4A that is important for limb outgrowth and expression of the fibroblast growth factor Fgf8 in zebrafish and chicks. Thalidomide initiates its teratogenic effects by binding to CRBN and inhibiting the associated ubiquitin ligase activity. This study reveals a basis for thalidomide teratogenicity and may contribute to the development of new thalidomide derivatives without teratogenic activity.

Pubmed ID: 20223979 RIS Download

Mesh terms: Animals | Carrier Proteins | Chick Embryo | Cullin Proteins | DNA-Binding Proteins | Embryo, Nonmammalian | Embryonic Development | Fibroblast Growth Factors | Forelimb | Gene Expression Regulation, Developmental | HeLa Cells | Humans | Mutant Proteins | Peptide Hydrolases | Teratogens | Thalidomide | Ubiquitin-Protein Ligases | Ubiquitination | Zebrafish | Zebrafish Proteins

Research resources used in this publication

None found

Research tools detected in this publication

None found

Data used in this publication

None found

Associated grants

None

GO (Data, Gene Annotation)

ZFIN (Data, Gene Expression)

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.